Pages

Monday, November 24, 2014

Parkinson's Disease sufferer to travel to Bristol for groundbreaking new treatment



By wbchris  |  Posted: November 24, 2014

29309612
Kay Cotton with her dog this summer
nt.
Kay Cotton, a West Briton columnist from Camborne, will be taking part in a trial to test whether a drug called GDNF can slow the course of the disease.

The clinical trial was first tested on 18 people to determine its safety, but will now be used on half of a further 36 people, including Mrs Cotton, who is not fazed by the prospect.
“This trial has given me some hope and I feel as though I have nothing to lose.

“It would be great to feel normal again and I can’t just sit here waiting, I have to do something about it.”
Ms Cotton, 57, has suffered from Parkinson’s for 10 years and has said she has been overwhelmed by the support of her friends and family.

It is hoped that an implant that delivers GDNF into the brain can stop dopamine-producing nerve cells from dying, a major symptom with Parkinson’s Disease.
“I’m not nervous as I live on my own and am younger than many of my friends who have the disease.

“I’m probably one of the more eligible people as at this point, I’m not too affected and it’s my responsibility to do something about it.
“I started to feel as if I had no purpose but this trial has given me a real boost and is a glimmer of hope for me.”

The project was originally shut down in 2006 after controversy regarding stem cells, but the revived £2million scheme has been funded by Parkinson's UK, with support from the Cure Parkinson's Trust and in association with the North Bristol NHS Trust.
During the nine month trial, half of the people taking part will take the real drug (GDNF), while half will receive an inactive placebo.

Not even doctors will be aware of who has been injected with what, but once the nine month period is complete, all of the participants would switch to the GDNF if it proves successful.
Ms Cotton will be travelling to Bristol on December 5 to meet with medical professionals to discuss the next phase of treatment.

No comments:

Post a Comment